Rapport Therapeutics reported exceptional Phase II data for RAP-219, a TARPγ8-specific AMPAR modulator aimed at drug-resistant focal onset seizures. The open-label study showed a median 78% reduction in clinical seizures and a 71% decrease in electrographic seizure biomarkers over eight weeks. The robust efficacy spurred plans for Phase III initiation in 2026, propelling the company’s valuation above $1 billion amid strong investor confidence.